Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki , FI-00014 Helsinki, Finland.
Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku , FI20014 Turku, Finland.
ACS Appl Mater Interfaces. 2015 Oct 21;7(41):23197-204. doi: 10.1021/acsami.5b07033. Epub 2015 Oct 12.
Over the past decade, the potential of polymeric structures has been investigated to overcome many limitations related to nanosized drug carriers by modulating their toxicity, cellular interactions, stability, and drug-release kinetics. In this study, we have developed a successful nanocomposite consisting of undecylenic acid modified thermally hydrocarbonized porous silicon nanoparticles (UnTHCPSi NPs) loaded with an anticancer drug, sorafenib, and surface-conjugated with heptakis(6-amino-6-deoxy)-β-cyclodextrin (HABCD) to show the impact of the surface polymeric functionalization on the physical and biological properties of the drug-loaded nanoparticles. Cytocompatibility studies showed that the UnTHCPSi-HABCD NPs were not toxic to breast cancer cells. HABCD also enhanced the suspensibility and both the colloidal and plasma stabilities of the UnTHCPSi NPs. UnTHCPSi-HABCD NPs showed a significantly increased interaction with breast cancer cells compared to bare NPs and also sustained the drug release. Furthermore, the sorafenib-loaded UnTHCPSi-HABCD NPs efficiently inhibited cell proliferation of the breast cancer cells.
在过去的十年中，人们研究了聚合结构的潜力，通过调节其毒性、细胞相互作用、稳定性和药物释放动力学，来克服与纳米药物载体相关的许多限制。在这项研究中，我们开发了一种由十一烯酸修饰的热烃化多孔硅纳米颗粒（UnTHCPSi NPs）组成的成功的纳米复合材料，该纳米复合材料负载有抗癌药物索拉非尼，并通过表面接枝七（6-氨基-6-脱氧）-β-环糊精（HABCD），以展示表面聚合官能化对载药纳米颗粒的物理和生物性质的影响。细胞相容性研究表明，UnTHCPSi-HABCD NPs 对乳腺癌细胞没有毒性。HABCD 还增强了 UnTHCPSi NPs 的悬浮性以及胶体和血浆稳定性。与裸 NPs 相比，UnTHCPSi-HABCD NPs 与乳腺癌细胞的相互作用明显增强，并且能够持续释放药物。此外，负载索拉非尼的 UnTHCPSi-HABCD NPs 有效地抑制了乳腺癌细胞的增殖。
